FDA Approves New Drug for Skin Cancer, Zolinza

Armen Hareyan's picture
Advertisement

Skin Cancer Drug Approval

Advertisement

The U.S. Food and Drug Administration (FDA) today approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.

Zolinza was approved as part of FDA's Orphan Drug program, which offers companies financial incentives to develop medications for diseases affecting fewer than 200,000 American patients a year.

Advertisement